https://www.selleckchem.com/products/etc-1002.html It has been well established in the world that lipid disorders promote the development of atherosclerosis and its clinical consequences. This study aimed to assess the impacts of a Persian medicinal (PM) compound on lipid profile. From June 21 to October 21, 2020, a randomized double-blind controlled clinical trial was conducted with 74 dyslipidemic patients, who were randomly divided into two equally populated groups one prescribed with a Persian medicinal herbal compound (  = 37) and a placebo group (  = 37). A Persian herbal medicine including fenugreek, sumac, and purslane is introduced. Biochemical parameters including 12-hour fasting serum levels of total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), very-low-density lipoprotein (VLDL), and triglyceride (TG) were measured before the initiation and after the completion of study protocol. Percent changes of biochemical parameters include the following intervention group = cholesterol 35.22, Tg 45.91, LDL 24.81, HDL 2.05, VLDL 8.94 and placebo group = cholesterol 6.94, Tg -7.3, LDL 7.37, HDL 2.88, VLDL -0.14. The serum levels of total cholesterol ( =0.01) and LDL ( =0.01) significantly decreased and no increase was recorded in HDL ( =0.03) levels over time in the intervention group. Furthermore, between-group analysis showed a statistically significant difference between the intervention and placebo groups in this regard. VLDL ( =0.2) and TG ( =0.2) levels also decreased, however not significantly. This study showed that a Persian medicinal herbal compound could be safe and beneficial to decrease the levels of serum cholesterol and LDL in dyslipidemic patients. However, larger long-term studies are recommended to clarify this effect. This study showed that a Persian medicinal herbal compound could be safe and beneficial to decrease the levels of serum cholesterol and LDL in dyslipidemic patients. However, larger long-term studies are